Q32 Bio

#药闻简讯# 2025 年 12 月 1 日 专注于开发治疗斑秃（AA）及其他自身免疫和炎症性疾病的临床阶段生物技术公司$Q32 Bio(QTTB)$ 今日宣布已将其 II 期补体抑制剂 ADX-097 出售给$Akebia Therapeutics(AKBA)$ 。
ADX-097 是 Q32 Bio 组织靶向补体抑制剂平台的首个产品候选药物，是一种人源化抗 C3...

$Q32 Bio(QTTB)$ 此前--该公司宣布已将斑秃药物候选药物ADX-097出售给Akebia Therapeutics

$Q32 Bio(QTTB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-308328  Size: 4 KB 网页链接

$Q32 Bio(QTTB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-26-032248  Size: 5 KB 网页链接

$Q32 Bio(QTTB)$ 144 Report of proposed sale of securities Accession Number: 0001950047-25-009643  Act: 33  Size: 4 KB 网页链接

$Q32 Bio(QTTB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-308327  Size: 4 KB 网页链接

$Q32 Bio(QTTB)$ 8-K Current report, item 5.02 Accession Number: 0001193125-25-326821  Act: 34  Size: 132 KB 网页链接

$Q32 Bio(QTTB)$ 8-K Current report, items 1.01, 1.02, 2.01, 7.01, 8.01, and 9.01 Accession Number: 0001193125-25-303115  Act: 34  Size: 176 KB 网页链接

$Q32 Bio(QTTB)$ 144 Report of proposed sale of securities Accession Number: 0001950047-25-009608  Act: 33  Size: 4 KB 网页链接

$Q32 Bio(QTTB)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001193125-25-278812  Act: 34  Size: 11 MB 网页链接

$Q32 Bio(QTTB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-26-032247  Size: 6 KB 网页链接

$Q32 Bio(QTTB)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-25-278805  Act: 34  Size: 382 KB 网页链接

$Q32 Bio(QTTB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-26-032246  Size: 5 KB 网页链接